Evidence map›Paper›PMID 34803693›Full record

ReviewFrontiers in pharmacology2021

The Role of SGLT2 Inhibitors in Atherosclerosis: A Narrative Mini-Review.

Aurélie Pahud de Mortanges, Dante Salvador, Markus Laimer, Taulant Muka, Matthias Wilhelm, Arjola Bano

Open access · goldAbstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Frontiers in pharmacology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 28 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
28citing papers in PubMed, 2 pooled it
5.0field-weighted citation impact, top 4% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

28 citing papers in PubMed, 2 syntheses or guidelines pooled it, 49 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Trial
  4. Article
  5. Review
  6. Article
  7. Review
  8. Review
  9. Review
  10. Review
  11. Review
  12. The Role of SGLT2 Inhibitors in Atherosclerosis: A Systematic Review.Journal of community hospital internal medicine perspectives · 2025
    Review
  13. Article
  14. Review
  15. Observational
  16. Review
  17. Review
  18. Article
  19. Article
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 3 institutions in 1 country.

Aurélie Pahud de MortangesFaculty of Medicine, University of Bern, Bern, Switzerland.
Dante SalvadorInstitute of Social and Preventive Medicine, University of Bern, Bern, Switzerland.
Markus LaimerDepartment of Diabetes, Endocrinology, Nutritional Medicine, and Metabolism, Inselspital, Bern University Hospital, University of Bern, Bern, Switzerland.
Taulant MukaInstitute of Social and Preventive Medicine, University of Bern, Bern, Switzerland.
Matthias WilhelmDepartment of Cardiology, Inselspital, Bern University Hospital, University of Bern, Bern, Switzerland.
Arjola BanoInstitute of Social and Preventive Medicine, University of Bern, Bern, Switzerland.
University of Bern · CHInstitute of Social and Preventive Medicine · CHUniversity Hospital of Bern · CH

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

atherosclerotic cardiovascular diseasediabetesreviewSGLT2-inhibitorssubclinical atherosclerosis

Identifiers

PMID34803693
PMCPMC8602558
OpenAlexW3213347026

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.